Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?
Author:
Affiliation:
1. Endocrinology & Nutrition, Cliniques universitaires St-Luc, Brussels, Belgium
2. Fondation Coeur & Artères, Lille, France
Publisher
Informa UK Limited
Subject
Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism
Link
https://www.tandfonline.com/doi/pdf/10.2217/clp.10.65
Reference132 articles.
1. Libby PL: The forgotten majority. Unfinished business in cardiovascular risk reduction. J. Am. Coll. Cardiol. 46, 1225–1228 (2005).
2. Fruchart J-C, Sacks F, Hermans MP et al.: Executive statement: the Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidemic patients. A condensed position paper by the Residual Risk Reduction Initiative (R3i). Diab. Vasc. Dis. Res. 5, 319–335 (2008).
3. Fruchart J-C, Sacks F, Hermans MP et al.; for the Residual Risk Reduction Initiative: The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol. 102(Suppl.), 1–34 (2008). Extensive, in-depth review provides not only a definition of residual vascular risk focusing on atherogenic dyslipidemia, the current scientific evidence and a call-toaction to reduce such unaddressed need in high-risk patients.
4. Jones PH: Expert perspective: reducing cardiovascular risk in metabolic syndrome and Type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. Am. J. Cardiol. 102, 41L–47L (2008).
5. Grundy SM, Cleeman JI, Merz CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227–239 (2004).
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Colchicine for the primary prevention of cardiovascular events;Cochrane Database of Systematic Reviews;2022-06-28
2. Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors as Adjuvant Treatments for Patients with Hypercholesterolemia Treated with Statin: A Systematic Review and Network Meta-analysis;Frontiers in Pharmacology;2022-04-04
3. High atherogenic risk concomitant with elevated HbA1c among persons with type 2 diabetes mellitus in North Ethiopia;PLOS ONE;2022-02-01
4. Novel advances in cardiac rehabilitation;Netherlands Heart Journal;2021-06-10
5. Improved risk assessment of coronary artery disease by substituting paraoxonase 1 activity for HDL-C: Novel cardiometabolic biomarkers based on HDL functionality;Nutrition, Metabolism and Cardiovascular Diseases;2021-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3